REFERENCES
- Buktus de Aguilar B., Girard I., D'avila Paskulin D., de Franca E., Dornelles C., Suparregui Dias F., Bonorino C., Sampaio Alho C. CD14 Expression in the first 24h of sepsis: effect of -260C>T CD14 SNP. Immun. Invest. 2008; 37(8)753–769
- Caputo M., Cerrone G. E., Mazza C., Cedola N., Targovnik H. M., Gustavo D. F. No evidence of association of CTLA-4 -318C/T, 159 C/T, 3′STR and SUMO4 163 AG polymorphism with autoimmune diabetes. Immun. Invest. 2007; 36(3)259–270
- El-Chennawi F. A., Auf F. A., Metwally S. S., Mosaad Y. M., El-Wahab M. A., Tawhid Z. E. HLA-class II alleles in Egyptian patients with hepatocellular carcinoma. Immun. Invest. 2008; 37(7)661–674
- Haidari M., Hajilooi M., Rezazadeh M., Rafiei A., Alavi S. A., Keramat F. Polymorphism in the promoter region of the CD14 Gene and susceptibility to Brucellosis. Immun. Invest. 2006; 35(2)239–245
- Kiszel P., Kovacs M., Szalai C., et al. Frequency of carriers of 8.1 ancestral haplotype and its fragments in two Caucasian populations. Immun. Invest. 2007; 36(3)307–319, 2007
- Namamori M., He R., Sang H., Ye R. Normal cell surface expression and selective loss of functions resulting from Phe110 to Ser and Cys126 to Trp substitutuions in the formyl peptide receptor. Immunol. Invest. 2004; 33(2)193–212
- Sebastiani G. D., Morozzi G., Bellisai F., et al. Anti-cofactor autoantibodies in Systemic Lupus Erythematosus: prevalence, clinical and HLA associations. Immun. Invest. 2008; 37(4)375–383